Pancragen is a synthetic peptide of four amino acids, amidated at one end, that researchers at the St. Petersburg Institute of Bioregulation and Gerontology designed around a four-residue motif shared across insulinotropic polypeptides, the hormones that stimulate insulin release [1]. It belongs to a group of short regulatory peptides that cross the cell membrane and the nuclear envelope and can change gene expression [14]. Its research identity is pancreatic: it is studied for the insulin-producing islet cells and the enzyme-secreting acinar cells of the pancreas [6][8], and for the metabolic changes seen in aging and type 2 diabetes [5].
Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology synthesized the tetrapeptide and reported it in 2005 [1]. He compared the amino acid sequences of insulinotropic polypeptides, found a shared four-residue fragment, and built an amidated version designed to survive the protein-digesting enzymes of the gut [1]. In rats with alloxan-induced diabetes, a chemical model of the disease, the peptide partially restored insulin synthesis and brought the slope of the sugar curve close to that of normal animals [1]. A 2007 paper calls the molecule pancragen, and a 2010 paper describes the same sequence as an endogenous tetrapeptide, meaning one the body makes [3][4].
The research potential is specific and well defined: a short peptide that might preserve or restore pancreatic cell function in aging and type 2 diabetes [5][8]. The evidence comes mostly from cultured human pancreatic cells, diabetic rats and old monkeys [10], with a single human study from 2011 [5]. As of October 2026, pancragen has no FDA-approved drug product [17], one small human study appears in the PubMed record [5], and no trial is registered on ClinicalTrials.gov [20].
Key takeaways
- Pancragen is a four-amino-acid peptide modeled on a shared fragment of insulinotropic hormones, and it is studied for the insulin-producing and enzyme-secreting cells of the pancreas [1][8].
- In a 2011 study of 63 older adults, pancragen lowered fasting and glucose-tolerance-test glucose and reduced insulin and insulin resistance in the group with type 2 diabetes, while untreated patients showed no change [5].
- The human record is one small study [5], and the laboratory work centers on changes in pancreatic differentiation genes [8], promoter methylation [12] and cell-survival markers [7].
How it works
A short peptide that may reach the nucleus
Pancragen is small enough to cross cell membranes, and a mechanistic idea places it in the nucleus [13][14]. A receptor is a protein on or in a cell that a signal molecule docks with to start a response. Short peptides of this class cross the plasma membrane and the nuclear envelope, and the 2020 review from the same group describes that access as the route to epigenetic regulation [14]. The evidence for direct interaction with histones and DNA comes from binding assays and docking models [9][13].
In a fluorescence-quenching assay, a method that measures how a peptide dims the light from labeled protein as it binds, the tetrapeptide and five other short peptides bound wheat histones H1, H2B, H3 and H4 [9]. Histones are the proteins that DNA wraps around to form chromatin, the packaged form of the genome, and their tails control which genes are available for transcription. Binding depended on the histone and on the peptide sequence, so the authors called it site specific [9]. Wheat histones are a plant model, so the result shows binding to plant histones, not to human chromatin.
A 2016 docking study extended the idea to DNA itself. Docking is a computational method that fits two molecules together and scores the fit. The authors built spatial models for 19 short peptides and modeled the peptide on the DNA sequence acct [13]. The published abstract reports a model rather than a measurement in a living cell [13].
Differentiation signals in pancreatic cells
Pancragen may push pancreatic cells toward the differentiated acinar and islet programs [6][8]. Differentiation is the process by which a general cell acquires the specific structure and job of a tissue. Two of the pancreas's main working cell types are acinar cells, which make and secrete digestive enzymes, and islet cells, which make insulin, glucagon and other hormones. Transcription factors are proteins that bind DNA and switch genes on or off, and the factors named here mark those two cell programs.
In cultures of human embryonic pancreatic cells, late-passage cultures, the laboratory equivalent of aging, expressed less CXCL12 and Hoxa3, two differentiation factors tied to pancreatic development [6]. Adding pancragen raised both markers, and the effect was larger in the aged cultures. The same experiment treated bronchial cells with bronchogen and fibroblasts with vesugen, and each peptide stimulated its matching tissue, which is the tissue specificity the authors report [6].
A second study measured a wider panel in pancreatic cell cultures. Pancragen raised the acinar factors Pdx1 and Ptf1a and the islet factors Pdx1, Pax6, Pax4, Foxa2 and Nkx2.2 in both young and aged cultures [8]. The authors proposed that this differentiation effect may underlie the peptide's anti-diabetic and anti-inflammatory activity [8]. The abstract reports marker expression, not insulin secretion or glucose control.
Promoter methylation and gene expression
A second line of work asks how pancragen changes gene activity over time. Methylation is a chemical tag added to DNA, usually at a cytosine followed by a guanine, that can silence a gene when it sits in the promoter, the control region in front of the gene. In aging pancreatic cell cultures, the promoter methylation patterns of PDX1, PAX6 and NGN3 changed with age and tracked the changes in expression. In bronchial cultures, NKX2-1 and SCGB1A1 behaved the same way [12].
In pancreatic cells, the methylation of the PDX1, PAX6 and NGN3 promoters changed with age and with peptide treatment, and the authors proposed that these changes might cause the age- and peptide-related shifts in expression [12]. The pattern was not universal: PAX4 methylation did not change and was unaffected by the peptide even though its expression shifted, and FOXA2 methylation changed with age and peptide without tracking expression [12]. A methylation change in a cultured cell is a mechanism hypothesis until it is shown in tissue.
Cell survival, proliferation and insulin synthesis
Pancragen may also keep aging pancreatic cells alive and dividing. Apoptosis is programmed cell death, the orderly self-destruction cells use to remove damaged or excess cells, and proliferation is the act of dividing. In aged human pancreatic cell cultures, the tetrapeptide raised the matrix metalloproteinases MMP2 and MMP9, the anti-apoptotic protein Mcl1, and the proliferation markers PCNA and Ki67, and it lowered the pro-apoptotic protein p53 [7]. Matrix metalloproteinases are enzymes that remodel the matrix around cells.
The 2005 paper proposed that the peptide activates the preproinsulin gene promoter through complementary interactions with DNA, a hypothesis built on sequence analysis rather than a binding experiment [1]. In rats with alloxan-induced diabetes, the peptide partially restored insulin synthesis and made the sugar curve resemble that of normal animals [1]. A 2007 study added a functional result: oral pancragen lowered blood glucose in streptozotocin-diabetic rats, and intramuscular pancragen normalized the adhesion of mesenteric capillary endothelial cells, the cells lining small vessels in the membrane that holds the intestines, without changing capillary permeability [3].
No cited abstract identifies a cell-surface receptor for pancragen; the mechanism rests on marker changes, binding models and whole-animal glucose data [1][8][13]. The primate work tests the endocrine claim directly: in old female rhesus monkeys, ten days of intramuscular pancragen raised the glucose disappearance rate and normalized the insulin and C-peptide response to a glucose load [10]. C-peptide is a fragment released when the body makes insulin, so it is a marker of the pancreas's own insulin production.
What has been studied in humans
Human data on pancragen come from one published study, a 2011 comparison of older adults at the Institute of Gerontology in Ukraine [5]. The investigators examined 30 healthy older adults and 33 with type 2 diabetes, the form of diabetes in which the body cannot use insulin properly and the pancreas gradually makes less insulin. Nocturnal melatonin production, the sleep-timing hormone from the pineal gland, was 70 percent lower in the diabetes group than in the healthy group.
Within the diabetes group, patients who received pancragen had lower fasting glucose and lower glucose during a standard glucose tolerance test, the timed sugar drink used to measure how quickly glucose clears [5]. Their plasma insulin and insulin resistance index, a calculated measure of how poorly insulin lowers glucose, also fell. Patients who did not receive the peptide showed no change in any carbohydrate measure. The abstract does not say how the treated and untreated patients were assigned, how many were in each subgroup, or what dose, route and duration were used.
The result is a signal from a small comparative study. The abstract reports no p-values, randomization, blinding or placebo control, and it gives no clinical outcomes such as weight, HbA1c or complications [5]. HbA1c is the share of hemoglobin that is glycated, a marker of average blood sugar over about three months. PubMed indexes no second human study, and a ClinicalTrials.gov search on October 23, 2026 returned no registered trial of pancragen [20].
No human pharmacokinetic data appear in the cited sources. No study in the sources measured how much pancragen reaches the blood or the pancreas after oral or intramuscular use, and the 2011 paper reports metabolic and melatonin endpoints [5]. That gap matters because the animal work used both routes, and the human result cannot be tied to an exposure [3][10].
Doses studied in human trials
As of October 2026, pancragen remains without an FDA-approved drug product, with one human study in the PubMed record and no registered clinical trial on ClinicalTrials.gov. Regimens below are those reported in the cited animal studies.
50 micrograms per animal per day intramuscularly for 10 days, with follow-up 3 weeks after the last dose
Old female rhesus monkeys
Pancragen 0.05 mg per animal per day intramuscularly for 10 days; glimepiride 4 mg per animal per day orally for 10 days
9 old female rhesus monkeys aged 20 to 25 years: 5 received pancragen and 4 received glimepiride
Lab and animal studies
Preclinical work on pancragen spans organotypic tissue culture, diabetic rodents, cultured human pancreatic cells and old primates. Organotypic culture is a method that keeps a slice of tissue alive with its architecture intact, which sits between a cell line and a whole animal [16].
In the 2006 organotypic study, pancreatic explants from 3-week-old and 18-month-old rats were exposed to 0.05 nanograms per milliliter of pancragen, and the peptide stimulated growth in the pancreatic cultures from both age groups [16]. The same experiment ran cardiogen, bronchogen and prostamax against heart, lung and prostate tissue, and each peptide acted on its matching tissue.
The diabetic rat work reported the metabolic effect. In alloxan-treated rats, the peptide partially restored insulin synthesis and produced a sugar curve close to normal [1]. In streptozotocin-treated Wistar rats, oral pancragen lowered blood glucose during treatment, while intramuscular pancragen normalized the adhesion of mesenteric capillary endothelial cells and left capillary permeability unchanged [3]. A morphology study from the same period reported a regulatory effect on pancreatic tissue morphology and function in diabetic rats [2].
The cultured-cell work adds detail. Human embryonic pancreatic cells showed lower CXCL12 and Hoxa3 expression in late-passage cultures, and pancragen raised both, with a larger effect in the aged cultures [6]. A second panel in pancreatic cultures showed higher Pdx1, Ptf1a, Pax6, Pax4, Foxa2 and Nkx2.2 with treatment in young and aged cells [8]. A third study reported higher MMP2, MMP9, Mcl1, PCNA and Ki67 and lower p53 in aged cultures [7].
The epigenetic experiments connect the marker changes to DNA. Methylation of the PDX1, PAX6 and NGN3 promoters changed with age and with peptide treatment in pancreatic cultures, and the authors proposed that the methylation pattern might drive the expression change [12]. Separate chemistry work showed that the peptide binds wheat histones H1, H2B, H3 and H4 site-specifically [9], and a docking study modeled it on the DNA sequence acct [13].
The primate studies are the strongest animal test of the endocrine claim. In old female rhesus monkeys, 50 micrograms per animal per day for 10 days intramuscularly raised the glucose disappearance rate and normalized the insulin and C-peptide response to a glucose load, and part of the effect persisted three weeks after the last dose [10]. A second primate study compared five old females given pancragen with four given glimepiride, a standard glucose-lowering drug: both lowered basal glucose, pancragen normalized insulin and C-peptide, and glimepiride produced a larger, delayed glucose drop [11]. The groups were small and there was no placebo arm.
The limits are consistent across the literature. Doses and group sizes are missing from several abstracts, Khavinson and colleagues contributed most of the work, and none of the abstracts reports a measurement of pancragen in blood or tissue [3][10]. The cell studies report marker expression rather than insulin secretion, and the animal studies report glucose and hormone curves rather than diabetic complications [8][10].
Research in detail
Comparative study in older adults, with treated and untreated patients in the diabetes group · 63 older adults: 30 healthy and 33 with type 2 diabetes
Pancragen lowered fasting and glucose-tolerance-test glucose and reduced plasma insulin and the insulin resistance index; patients who did not receive the peptide showed no change in carbohydrate metabolism.
Evidence scope: The abstract reports no dose, route, duration, randomization, blinding or p-values, and gives no clinical outcomes; the number of treated patients is not stated. Abstract reviewed; full text not read.
Glucose-tolerance study in old female primates, with treatment and follow-up after withdrawal · Old female rhesus monkeys
Pancragen raised the glucose disappearance rate and normalized the insulin and C-peptide response to a glucose load, and part of the effect remained 3 weeks after treatment stopped.
Evidence scope: The abstract does not state the number of animals, the control group or the allocation method. Abstract reviewed; full text not read.
Comparison of pancragen with glimepiride, a standard glucose-lowering drug, in old female primates · 9 old female rhesus monkeys aged 20 to 25 years: 5 received pancragen and 4 received glimepiride
Both drugs lowered basal glucose; pancragen normalized insulin and C-peptide, while glimepiride produced a stronger, delayed glucose drop and C-peptide stimulation without a significant insulin effect.
Evidence scope: Very small groups, no placebo arm, different routes. Abstract reviewed; full text not read.
Animal study in a chemical model of diabetes · Rats with alloxan-induced diabetes
The tetrapeptide partially restored insulin synthesis and the slope of the sugar curve resembled that of normal animals; the authors proposed activation of the preproinsulin promoter through DNA sequence complementarity.
Evidence scope: The abstract gives no dose, group size or statistical analysis, and the promoter mechanism is a hypothesis. Abstract reviewed; full text not read.
Animal study comparing oral and intramuscular routes in streptozotocin-diabetic rats · Wistar rats with streptozotocin-induced diabetes
Oral pancragen produced a pronounced hypoglycemic effect during treatment; intramuscular pancragen normalized the adhesion of mesenteric capillary endothelial cells but did not change capillary permeability.
Evidence scope: The abstract gives no doses, group sizes or treatment duration. Abstract reviewed; full text not read.
Human embryonic pancreatic and bronchial cell cultures at early and late passage, with matched peptides for each tissue · Cultured human embryonic pancreatic cells, bronchial cells and prostatic fibroblasts
Pancragen raised CXCL12 and Hoxa3 in pancreatic cells, with a larger effect in aged cultures; bronchogen acted on bronchial cells and vesugen on fibroblasts, showing tissue specificity.
Evidence scope: Cell-culture markers only, no insulin secretion or glucose control. Abstract reviewed; full text not read.
Pancreatic cell cultures from young and aged groups, with a panel of differentiation markers · Cultured pancreatic cells
Pancragen raised the acinar factors Pdx1 and Ptf1a and the islet factors Pdx1, Pax6, Pax4, Foxa2 and Nkx2.2 in both young and aged cultures, where marker expression had fallen with age.
Evidence scope: Marker expression in cultured cells, with no insulin secretion, glucose control or in vivo confirmation. Species not stated in the abstract; abstract reviewed; full text not read.
History and where it stands today
Pancragen moved from a sequence comparison in 2005 to cell-culture, rodent and primate studies, with one human study and no registered program [20].
- 2005Khavinson synthesizes the tetrapeptide from a shared four-residue fragment of insulinotropic polypeptides and reports partial restoration of insulin synthesis in rats with alloxan-induced diabetes [1].
- 2006An organotypic tissue-culture study finds that 0.05 nanograms per milliliter of pancragen stimulates pancreatic explants from young and aged rats, alongside matching peptides for heart, lung and prostate tissue [16].
- 2007One rat paper reports a regulatory effect on pancreatic morphology and function in experimental diabetes [2], and another reports a fall in blood glucose after oral dosing and normalized adhesion of mesenteric capillary endothelial cells [3].
- 2010A 2010 paper tests the natural tetrapeptide across ontogeny and in streptozotocin-induced diabetes, using a set of metabolic parameters that describe apoptosis [4].
- 2011Korkushko and colleagues report the only human study in the PubMed record: 30 healthy older adults and 33 with type 2 diabetes, with lower fasting and glucose-tolerance-test glucose, insulin and insulin resistance in those given pancragen [5].
- 2012 to 2013Cell-culture papers show higher CXCL12 and Hoxa3, a broader panel of acinar and islet transcription factors, and higher survival and proliferation markers in pancreatic cell cultures, including aged human cells [6][7][8].
- 2013 to 2016The peptide binds wheat histones site-specifically [9], old-monkey work reports increased glucose disappearance and normalized insulin responses [10][11], promoter methylation changes appear in treated pancreatic cells [12], and a docking study models the peptide on the DNA sequence acct [13].
- 2020 to 2025Two reviews discuss the peptide among short peptides that influence pancreatic cell differentiation, and the 2025 review places it with peptides studied for stem cell fate and tissue engineering [14][15].
- October 2026As of October 2026, pancragen has no FDA-approved drug product, one published human study and no registered trial on ClinicalTrials.gov [5][17][20]. WADA's 2026 list does not name it, and S0 covers substances without government approval for human therapeutic use; no FDA approval for pancragen appears in the cited sources. The NCAA 2026-27 list does not name it either, with class 6 covering peptide hormones, growth factors, related substances and mimetics and the NCAA page explaining the class [18][19].
How it compares with related peptides
Bronchogen is a tetrapeptide tested alongside pancragen in the same 2012 study: pancragen raised CXCL12 and Hoxa3 in pancreatic cells while bronchogen did the same in bronchial epithelial cells, and each peptide raised its markers in its own tissue [6]. The 2015 methylation study used the same peptide pair and found tissue-specific promoter changes [12]. Bronchogen is studied for lung tissue, and pancragen for pancreatic tissue.
Vesugen is a tripeptide from the same series, and the 2012 experiment used it on prostatic fibroblasts while pancragen acted on pancreatic cells, and the same experiment showed tissue specificity across three cell types [6]. The 2020 review places short peptides of this kind among the molecules that direct cell differentiation [14]. Vesugen is the shorter, three-amino-acid relative in the same series.
Cardiogen is another peptide tested alongside pancragen in the 2006 organotypic study, where each peptide stimulated its matching tissue: pancragen the pancreas and cardiogen the heart [16]. Both are studied as tissue-specific regulators. Cardiogen covers the cardiac side.
Side effects and safety signals
The safety record is thin: one small human study, two short primate courses and rodent work, with no toxicology study in the cited sources.
- No adverse events are reported in the 2011 human study: the abstract describes the metabolic and melatonin results and does not mention safety monitoring, so the human safety record is essentially uncharacterized [5].
- The human data come from one study of 63 older adults, with no reported duration, so it cannot detect uncommon or delayed effects [5].
- In old female rhesus monkeys, a 10-day intramuscular course was described as safe, and the glucose effect persisted for three weeks after the last dose [10][11].
- The 2015 primate comparison found that pancragen lowered basal glucose, while glimepiride produced a stronger, delayed glucose drop, a difference that could matter for glucose control [11].
- The rodent studies report glucose lowering and pancreatic changes but no toxicology, histopathology or repeat-dose safety endpoints in their abstracts [2][3].
- No pharmacokinetic or toxicokinetic study in any species appears in the sources, so tissue exposure after a given amount is unmeasured [5][10].
- Long-term safety is unknown: the published courses were 10 days in primates and of unstated length in the human study [5][10].
- Identity and purity of a research peptide rest on the certificate of analysis, and the COA library collects published test results.
The future: what's next for Pancragen
No trial is registered on ClinicalTrials.gov [20]. A ClinicalTrials.gov search on October 23, 2026 returned no study of pancragen, and the cited papers contain no registered protocol or sponsor announcement. The next human step would be a randomized trial with a stated dose, route and duration, because the 2011 study leaves all three unstated [5].
The animal program points to the questions a trial would need to answer. Ten-day courses in old monkeys changed glucose, insulin and C-peptide, and part of the effect lasted three weeks after the last dose [10][11]. Whether a longer course keeps the effect, and whether it lowers glucose enough to matter in type 2 diabetes, is untested. No repeat-dose toxicology package or pharmacokinetic study appears in the sources [5].
Regulatory dates are absent. No FDA advisory committee review, user fee action or approval decision for pancragen appears in the sources, and the openFDA Drugs@FDA query returns no application [17]. WADA's 2026 list and the NCAA 2026-27 list do not name the peptide; S0 covers substances without government approval for human therapeutic use, and class 6 covers peptide hormones, growth factors, related substances and mimetics, with the NCAA list banning chemically or pharmacologically related substances [18][19]. A decision date would only follow a sponsor filing.
- No cited abstract identifies a receptor or direct binding partner for pancragen in human cells, and the histone and DNA work used binding assays and docking models [9][13].
- Whether the 2011 glucose and insulin changes hold in a randomized, blinded trial is unknown [5].
- How much peptide reaches the blood and pancreas after oral or intramuscular use has not been measured in humans [5][10].
- Whether the differentiation-marker shifts in cultured cells produce more working islet cells in a living animal is untested; the cited cell studies do not test it [6][8].
- Whether long-term use carries hypoglycemia or other metabolic risk is unknown [11].